Brainmax® is a new neuroprotection technology from Promomed Group of Companies

Promomed Group of Companies has registered a new drug Brainmax^®, reaffirming the commitment to the strategy of launching innovative, intellectually capacious products. The technology developed by the company for combining components in one dosage form has made it possible to obtain a unique medicinal product with high therapeutic potential. The new drug uses the synergy of two components to protect, ensure the functioning and repair of cells of the nervous system in extreme conditions of oxygen starvation, including against the background of infections and in the post-infection period.

A proprietary drug containing a combination of ethylmethylhydroxypyridine succinate and meldonium has added to the company's portfolio of drugs to combat COVID-19 and its consequences. The active ingredients of the new drug have a wide range of effects, and due to synergy they have stress-protective, antihypoxic, anticonvulsant properties, are able to optimize cell function, restoring the processes of oxygen delivery to the cell itself and its consumption even in conditions of forced hypoxia.

Brainmax^® It has three key mechanisms of action: neuroprotection, neuroregeneration and neuroactivation or neuro-protection, restoration and activation. This allows the drug to be used in the complex therapy of acute and chronic cerebral circulatory disorders, mild cognitive disorders, decreased performance, as well as to support the body during mental and physical overloads, including in athletes. The drug is relevant for the rehabilitation of patients after COVID-19.

"The majority of adults worldwide, especially residents of large cities, suffer from mental and physical overloads. In some cases, these conditions require medical support to protect, restore, and increase body activity. The new drug is intended for the treatment of acute and chronic cerebral circulatory disorders, as well as for improving performance and helping the body with asthenic conditions that can develop, including as a result of COVID-19, stress, overwork and other diseases and conditions," she said. Kira Zaslavskaya, Director of New Products, Promomed Group.

Due to enhanced neuroprotection, the drug actively protects the cells of the nervous system, restores damaged neurons and activates the brain. This allows you to achieve maximum efficiency in the fight against increased fatigue, helps to improve performance and tolerance of mental and physical exertion, and recover quickly even under stress.

Brainmax^® It will be produced at the Biochemist plant (part of the Promomed group) using full–cycle technology - from the active pharmaceutical substance to the finished dosage form. The drug will be available in the form of capsules with a dosage of 250+ 250 mg of each active substance, 40 and 60 pieces per pack, which corresponds to current treatment regimens.